Literature DB >> 6352014

Host resistance to metastasis from mouse mammary carcinomas.

J Vaage, D Glaves-Rapp.   

Abstract

Although undisturbed primary mouse mammary tumors may give rise to overt metastases, these have generally been observed near the terminal stage of progressive tumor growth. Unlike malignant breast disease in women, metastases are seldom the cause of death in mice, and in some strains as few as 2% of mammary tumor hosts may be affected (1). Highly metastatic tumors may, of course, be found, and hosts of the mammary carcinoma WHT all develop metastases (2). Evidence from animal models suggests that host defense reactions against immunogenic tumors may affect the incidence of metastatic spread (3-5). But nonimmunogenic and weakly immunogenic tumors probably represent the majority of mammary carcinomas (2, 6, 7), and this class was once considered outside control by the host. However, natural protective factors are also known which may prevent metastasis independently of specific antitumor immunity (8-10). There are therefore most likely several different biological factors and mechanisms which prevent circulating, viable cancer cells from developing into metastases. But one can not yet generalize whether natural resistance factors or induced resistance factors are the most important, or whether any resistance factors are as important in preventing metastases as is the basic unacceptability of cells in heterotopic locations. This review will not attempt to present a comprehensive analysis of cell-mediated and humoral immunity to mouse mammary tumors because this topic has recently been exhaustively treated in the reviews by Stutman (11) and Blair (12). We will focus primarily on information from in vivo investigations of the role of host resistance in the control of mammary tumor cells progressing through successive levels of metastasis from the primary tumor, through lymphatic or hematogenous dissemination, to colonization of distant organs.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6352014     DOI: 10.1007/bf00048969

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  60 in total

1.  Stimulation or inhibition of immune resistance against metastatic or local growth of a C3H mammary carcinoma.

Authors:  J Vaage; S Agarwal
Journal:  Cancer Res       Date:  1976-05       Impact factor: 12.701

2.  The use of replacement transfusion in diseases other than hemolytic disease of the newborn.

Authors:  M BESSIS
Journal:  Blood       Date:  1949-04       Impact factor: 22.113

Review 3.  Tumor angiogenesis.

Authors:  J Folkman
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

4.  Metastatic incidence of a spontaneous murine mammary adenocarcinoma.

Authors:  J C Anderson; R A Fugmann; R L Stolfi; D S Martin
Journal:  Cancer Res       Date:  1974-08       Impact factor: 12.701

Review 5.  Nonimmunological host defenses: a review.

Authors:  C A Apffel
Journal:  Cancer Res       Date:  1976-05       Impact factor: 12.701

6.  Myofibroblastic contraction in spontaneous regression of multiple congenital mesenchymal hamartomas.

Authors:  S P Benjamin; R D Mercer; W A Hawk
Journal:  Cancer       Date:  1977-11       Impact factor: 6.860

7.  The regional lymph node in cancer. Relationship of nodal histologic findings to cytotoxicity and immunity.

Authors:  E R Fisher; B Fisher; E Saffer
Journal:  Arch Pathol Lab Med       Date:  1977-03       Impact factor: 5.534

8.  Malignant cell arrest in thymus and spleen of mice bearing transplanted tumors.

Authors:  N Haran-Ghera; R Krauthgamer; A Peled
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Quantitative studies of translymphnodal passage of tumour cells naturally disseminated from a non immunogenic murine squamous carcinoma.

Authors:  H B Hewitt; E Blake
Journal:  Br J Cancer       Date:  1975-01       Impact factor: 7.640

10.  Failure of preoperative C. parvum vaccine to modify secondary disease following excision of two non-immunogenic murine carcinomas.

Authors:  H B Hewitt; E R Blake
Journal:  Br J Cancer       Date:  1978-08       Impact factor: 7.640

View more
  1 in total

1.  The mutationally activated Met receptor mediates motility and metastasis.

Authors:  M Jeffers; M Fiscella; C P Webb; M Anver; S Koochekpour; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.